Marker Therapeutics, Inc. (MRKR)
NASDAQ: MRKR · Real-Time Price · USD
1.180
-0.060 (-4.84%)
At close: Sep 4, 2026, 4:00 PM EDT
1.200
+0.020 (1.69%)
After-hours: Sep 4, 2026, 7:57 PM EDT

Marker Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
3.553.556.593.313.511.24
Revenue Growth
-15.11%-46.19%99.06%-5.76%182.96%166.01%
Cost of Revenue
8.8111.813.4710.4211.9727.79
Gross Profit
-5.26-8.25-6.88-7.11-8.45-26.55
Selling, General & Admin
4.244.184.247.4811.3412.92
Operating Expenses
4.244.184.247.4811.3412.92
Operating Income
-9.5-12.44-11.12-14.58-19.79-39.48
Interest & Investment Income
0.550.590.440.540.250.01
Other Non Operating Income (Expenses)
0.230.12----
EBT Excluding Unusual Items
-8.72-11.73-10.68-14.04-19.54-39.47
Other Unusual Items
--0.45---0.23-2.41
Pretax Income
-8.72-12.18-10.68-14.04-19.78-41.88
Income Tax Expense
-0.02-0.020.050--
Earnings From Continuing Operations
-8.71-12.16-10.73-14.05-19.78-41.88
Earnings From Discontinued Operations
---5.81-10.15-
Net Income
-8.71-12.16-10.73-8.24-29.93-41.88
Net Income to Common
-8.71-12.16-10.73-8.24-29.93-41.88
Net Income Growth
------
Shares Outstanding (Basic)
19159988
Shares Outstanding (Diluted)
19159988
Shares Change
73.22%70.49%1.94%5.49%9.16%62.64%
EPS (Basic)
-0.47-0.79-1.19-0.94-3.58-5.47
EPS (Diluted)
-0.47-0.79-1.19-0.94-3.59-5.47
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-9.76-12.01-10.91-16.44-26.97-30.41
Free Cash Flow Per Share
-0.52-0.79-1.22-1.87-3.23-3.98
Gross Margin
-148.28%-232.68%-104.33%-214.60%-240.64%-
Operating Margin
-267.95%-350.67%-168.69%-440.37%-563.28%-3179.32%
Profit Margin
-245.51%-342.96%-162.82%-248.76%-851.87%-3372.68%
Free Cash Flow Margin
-275.09%-338.74%-165.53%-496.51%-767.66%-2449.11%
EBITDA
----11.79-17-37.33
D&A For EBITDA
---2.792.792.15
EBIT
-9.5-12.44-11.12-14.58-19.79-39.48
EBIT Margin
-267.95%--168.69%---
Revenue as Reported
3.553.556.593.313.511.24
SEC Filings: 10-K · 10-Q